In Teva Canada Ltd v Pfizer Canada Inc,
the Supreme Court of Canada (the "SCC") held Pfizer's
Canadian Patent No. 2,163,446 (the '446 Patent) to be
"void" for not disclosing that sildenafil, the active
ingredient in ViagraTM, was the compound that had been
demonstrated to work in patients. (Please click here for further details.) The SCC has now
revised and clarified the wording of its decision. However, the
immediate effect of the revised decision on the marketplace has not
changed because generic sildenafil still has marketing
authorization and is available for sale in Canada.
The Background
The holding by the SCC that the '446 Patent was
"void" was unusual in that the appeal had originated as an application brought by Pfizer
under the Patented Medicines (Notice of Compliance) Regulations
(the "PM(NOC) Regulations"). Teva (then Novopharm)
had asserted to the regulator, Health Canada, that the '446
Patent was invalid and therefore should not prevent Teva